Ricolinostat

Drug Profile

Ricolinostat

Alternative Names: ACY-1215; ACY-63; Rocilinostat

Latest Information Update: 23 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Columbia University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Regenacy Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Lymphoma
  • Phase I Breast cancer; Chronic lymphocytic leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Malignant melanoma; Peripheral nervous system diseases

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Dec 2017 Regenacy Pharmaceuticals plans a phase II trial for Diabetic neuropathies in 2018 (NCT03176472)
  • 01 Apr 2017 Preclinical trials in Malignant melanoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top